Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Jul 18, 2021 4:15pm
142 Views
Post# 33567158

RE:RE:RE:Dose escalation

RE:RE:RE:Dose escalationReaching a high MTD is important because it would be a good predictor of efficacy, but it would be more than that. It would point to the demonstration of the proof of concept, which is the ability of TH19P01 to concentrate a cytotoxic drug in the cancer cells. If you can establish that proof, it opens the doors to a wide array of othe PDC combination with other cytotoxic agents. So the key here is not just proving that concentrating docetaxel in advanced cancers can be efficacious, the othe key is to prove the ability of TH19P01 to concetrate a drug in cancer cells. If it works with docetaxel, it is very likely to work with many other drug. So efficacy proof is good for TH1902, but proof of concept is good because it valdates the whole platform.
<< Previous
Bullboard Posts
Next >>